A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

NCT04733417 | Unknown Phase 2

• 1 other identifier: BC-IIT-SHR6390-FMTN
• Study Type: interventional
• Target: 35
• Locations: 1 country
• Sites: 1

Brief Summary

The study is being conducted to assess the efficacy and safety of SHR6390 combined with famitinib in the treatment of advanced or metastatic breast cancer that progress in 1-2 line endocrine therapy.

Conditions

Advanced Breast Cancer; Metastatic Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Objective response rate (ORR)

  ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) according to RECIST 1.1.

  From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months.

Secondary Outcomes (5)

• Clinical benefit rate (CBR)

  Randomization in participants with measurable disease at baseline through the end of study (12 months after the last participant is enrolled).

• Duration of Remission (DoR)

  From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months.

• Progression Free Survival (PFS)

  Randomization to the first occurrence of disease progression as determined by the investigator according to (RECIST v1.1 ) or death from any cause, until the end of study (12 months after the last participant is enrolled)

• Overall Survival (OS)

  Randomization to the first occurrence of disease progression as determined by the investigator according to (RECIST v1.1 ) or death from any cause, until the end of study (12 months after the last participant is enrolled)

• Safety Profile

  From the first medication to 28 days after the end of treatment.

Study Arms (1)

SHR6390+famitinib

EXPERIMENTAL

Participants will receive SHR6390 in combination with famitinib.

Drug: SHR6390; Drug: famitinib

Interventions

SHR6390 DRUG

SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.

SHR6390+famitinib

famitinib DRUG

Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3.

SHR6390+famitinib

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female subjects aged 18 to 75 years old
• ECOG performance status 0-1;
• Life expectancy is not less than 12 weeks;
• Histological or cytological confirmation of HR+/HER2- recurrent/metastatic breast cancer;
• Participants must not have received more than two prior lines of hormonal therapy;
• Participants must not have received more than two prior lines of chemotherapy in recurrence or metastatic setting. In addition, participants must have been treated with taxanes.
• Participants with measurable disease must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST1.1. Participants must have experienced disease recurrence or progression during or after last therapy;
• Adequate function of major organs
• Participants who have not received anticoagulation therapy: INR≤1.5, APTT≤1.5 ULN. Participants receiving full-dose or parenteral anticoagulation therapy had a stable dose of anticoagulant for more than 2 weeks before entering the clinical study, the result of the coagulation test is within the normal range;
• Women of childbearing potential who have a negative pregnancy test within 14 months before enrollment and willing to use adequate contraception prior to enrollment and for the duration of study participation;
• No radiotherapy, chemotherapy, molecular targeted therapy, immunotherapy, or surgery were received within 4 weeks before enrollment, and the toxicity of the previous treatment has been restored to ≤1 grade (such as surgery, the wound has healed completely); no endocrine therapy within 7 days before enrollment;
• Voluntary participation in the study, signed informed consent, good compliance and willingness to cooperate with follow-up.

You may not qualify if:

• Participants who previously received VEGFR TKI;
• Participants who previously received CDK4/6 inhibitor;
• Allergy to study drug or its components;
• Metastasis history of the central nervous system, or brain imaging at baseline or clinical evidence suggests the presence of CNS;
• Participated in other drug clinical trials within 4 weeks before the first dose;
• Other malignancies within 5 years, except cured in-situ of uterine cervix carcinoma , skin basal cell carcinoma and squamous-cell carcinoma
• History of heart disease: uncontrollable hypertension (\>140/90 mm Hg), hypertensive crisis or hypertensive encephalopathy, ≥ Grade II myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (≥Grade 2, QTc interval ≥470 ms), can't stop taking drugs that may prolong QT (such as antiarrhythmic drugs) during the study; Ⅲ \~ Ⅳ stage heart failure(according to NYHA), or LVEF \<50%;
• Abnormal coagulation function (INR\>1.5 or PT \>ULN+4 seconds or APTT\>1.5 ULN), have bleeding or thrombotic tendency or receiving thrombolytic or anticoagulant therapy;
• A history of bleeding, with clinically significant bleeding symptoms or clear bleeding tendency within 3 months before enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ≥++, or vasculitis;
• Arterial/venous thrombosis occurred within one year before screening;
• Tumor has invaded important blood vessels or the tumor is likely to invade important blood vessels and cause fatal hemorrhage during treatment; thyroid function is abnormal, even treatment cannot maintain normal thyroid function;
• Urine routine test indicates urine protein ≥(++), or 24-hour urine protein ≥1.0g;
• Long-term unhealed wounds or fractures;
• Received major surgery or suffered severe traumatic injury, fracture or ulcer within 4 weeks after enrollment;
• Poor absorption of oral drugs, such as inability to swallow, chronic diarrhea and intestinal obstruction;

Sponsors & Collaborators

• Tianjin Medical University Cancer Institute and Hospital: lead
• Jiangsu HengRui Medicine Co., Ltd.: collaborator

Study Sites (1)

Breast Oncology, Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300060, China

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

famitinib

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 30, 2020
• First Posted: February 2, 2021
• Study Start: May 26, 2021
• Primary Completion: August 30, 2022
• Study Completion: September 30, 2023
• Last Updated: April 13, 2023

Record last verified: 2022-04

Locations

CN (1)